BioCentury
ARTICLE | Financial News

AgomAb emerges from stealth with €21M series A

April 3, 2019 8:39 AM UTC

Agonist antibody company AgomAb emerged from stealth with a €21 million ($24 million) series A round led by V-Bio Ventures and Advent France Biotechnology to develop antibodies mimicking growth factors for tissue regeneration.

AgomAb Therapeutics N.V. (Ghent, Belgium) also announced the hiring of Tim Knotnerus as CEO and Torsten Dreier as chief development officer. Knotnerus was VP corporate development at AM-Pharma B.V. (Bunnik, the Netherlands). Dreier was co-founder and chief development officer at argenx S.E. (Euronext:ARGX; NASDAQ:ARGX). John Haurum, most recently CEO of F-star Biotechnology Ltd. (Cambridge, U.K.), joins as chairman of the newco...